ClinicalTrials.gg
Active, not recruitingNCT07911943Updated Nov 3, 2026

Comparison of Analgesic Efficacy Between Ultrasound Guided Serratus Anterior Plane Block or Thoracic Paravertebral Block Versus Intravenous Fentanyl for On-pump Coronary Artery Bypass Graft Surgery

A Phase 1 interventional study of Serratus Anterior Plane Block (SAPB) group and Thoracic paravertebral block (TPVB) in Intra and Post Operative Pain Management and Fast Track Program,(Enhanced Recovery After Surgery (ERAS)), sponsored by Ain Shams University. Active, not recruiting at 1 site in Egypt. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Ain Shams University · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jan 2026, registered Oct 2026).
Updated Nov 3, 2026Newly registeredGo to Updates ↓
Phase
Phase 1
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Study summary

Aim is to compare intra and postoperative analgesic efficacy of US-guided serratus anterior plane block (SAPB) or thoracic paravertebral block (TPVB) versus intravenous fentanyl in patient undergoing on-pump CABG surgery.

Read the detailed description

Aim is to compare intra and postoperative analgesic efficacy of US-guided serratus anterior plane block (SAPB) or thoracic paravertebral block (TPVB) versus intravenous fentanyl in patient undergoing on-pump CABG surgery.

The enrolled (111) patients will be randomly assigned via a computer-generated randomization table into three parallel and equivalent (1:1:1 ratio) groups: group A (37); will receive serratus anterior plane block, group B (37);will receive thoracic paravertebral block and group C (37); standard of care control group, will receive fentanyl infusion.

Group (A):

SAPB block will be performed Bilaterally. 20 ml of 0.25% bupivacaine hydrochloride [Maracine prepared by adding an equal volume (1:1) of normal saline (0.9%) to 0.5% bupivacaine]will be injected.

Group (B):

TPVB will be performed bilaterally. 20 ml of 0.25% bupivacaine [Maracine prepared by adding an equal volume (1:1) of normal saline (0.9%) to 0.5% bupivacaine] will be injected.

Group (C) (Control):

Patient will receive IV fentanyl infusion just before skin incision, which will be stopped when cardiopulmonary bypass (CPB) is on, then resumed after weaning form CPB and continued till the end of the surgery.500µg fentanyl will be mixed with 50 ml 0.9% normal saline in 50 ml syringe (10 µg /ml).Infusion rate will be determined according to a dose of 1µg /kg/h.

02

Conditions studied

  • Intra and Post Operative Pain Management
  • Fast Track Program,(Enhanced Recovery After Surgery (ERAS))

Browse trials for

03

In context

Pain, Postoperative

5,640 studies on the registry are indexed under Pain, Postoperative; 1,230 are open to participants now.

This study's planned enrollment of 111 is above the median of 75 across 4,821 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Ain Shams University is the lead sponsor of 1,950 studies on the registry; 429 are open to participants now.

Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 40-70 years.
  2. Sex: Males and Females.
  3. American Society of Anaesthesiologists (ASA) Physical Status Class III.
  4. Scheduled for elective on-pump isolated CABG via median sternotomy for 1 or 2 coronary vessel grafts.
  5. Good left ventricular systolic function with (EF) >50%

Exclusion criteria

Exclusion Criteria:

  1. Declining to give a written .
  2. History of allergy to the medications used in the study.
  3. to regional anaesthesia as patient refusal, coagulopathy [ ≥45 sec, prothrombin time (INR) 1.5, ≤ 80,000/dl], clopidogrel within the last 7 days of the procedure, severe spinal deformity or infection at puncture site).
  4. Psychiatric disorders or significant cognitive dysfunction.
  5. American Society of Anaesthesiologists (ASA) Physical Status Class IV or higher.
  6. Chronic use of opioids.
  7. Morbid obesity ( > 40 kg/m2).
  8. Patient with severe pulmonary disease.
  9. Patient who requires emergency CABG operation or redo cardiac surgery.
  10. Post operative intra-aortic balloon or extracorporeal membrane oxygenation (ECMO).
  11. Patient who will be operated for bleeding, tamponade or any reason for revision postoperatively.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
111 participants (estimated)

Study arms

  • Active comparator
    serratus anterior plane block

    this group will be given 20 ml of 0.25% bupivacaine hydrochloride bilaterally

    Procedure: Serratus Anterior Plane Block (SAPB) group

  • Active comparator
    thoracic paravertebral block

    this group will be given 20 ml of 0.25% bupivacaine hydrochloride bilaterally

    Procedure: Thoracic paravertebral block (TPVB)

  • Other
    control

    Intravenous fentanyl infusion 1µg /kg/h

    Drug: Intravenous fentanyl 1 μg∙kg-1

Interventions

  • ProcedureSerratus Anterior Plane Block (SAPB) group

    In SAPB; the needle is advanced in-plane from caudally cephalad at the midaxillary line at the level of the fourth rib with 45-degree angle, targeting the plane between the latissimus dorsi and serratus muscles. SAPB block will be performed Bilaterally. After confirmation that the needle tip is in the correct plane by injecting 2 ml of saline, 20 ml of 0.25% bupivacaine hydrochloride \[Maracine prepared by adding an equal volume (1:1) of normal saline (0.9%) to 0.5% bupivacaine\]will be injected, with intermittent aspiration to confirm neither air nor blood in the needle.

  • ProcedureThoracic paravertebral block (TPVB)

    In TPVB; the needle is advanced in parasagittal plane over the transverse processes of the T4 and T5 vertebrae, about 2.5 cm lateral to the spinous processes, just deep to the superior costotransverse ligament but superficial to the parietal pleura. TPVB will be performed bilaterally. After confirmation that the needle tip is in the correct plane by injecting 2 ml of saline, 20 ml of 0.25% bupivacaine \[Maracine prepared by adding an equal volume (1:1) of normal saline (0.9%) to 0.5% bupivacaine\] will be injected, with intermittent aspiration to confirm no air or blood in the needle.

  • Patient will receive IV fentanyl infusion just before skin incision, which will be stopped when cardiopulmonary bypass (CPB) is on, then resumed after weaning form CPB and continued till the end of the surgery.500µg fentanyl will be mixed with 50 ml 0.9% normal saline in 50 ml syringe (10 µg /ml).Infusion rate will be determined according to a dose of 1µg /kg/h.

06

What researchers measure

Primary outcomes

  1. Duration of analgesia in hours

    Time frame: up to 12 hours

  2. Postoperative visual analogue pain score (VAS)

    Postoperative visual analogue pain score (VAS): It will be recorded every 1 hour after admission to ICU for the first 4 hours ' then every 2 hours for the remaining 8 hours

    Time frame: up to 12 hours

  3. Total dose of fentanyl

    Total doses of intra , postoperative fentanyl consumption and doses of rescue fentanyl.

    Time frame: up to 18 hours

Secondary outcomes

  1. Intra and postoperative haemodynamic data

    Mean blood pressure (mmHg): Baseline, immediately after performing the block, at 30 minutes intervals (except when the patient on CPB) till the end of surgery Mean blood pressure (mmHg): Immediately after ICU admission, at 1 hour intervals in the 1st 6 hours, then at 2 hours intervals till 12 hours

    Time frame: up to 18 hours

  2. Postoperative extubation time

    Postoperative extubation time in minutes.

    Time frame: for 12 hours

  3. Patients with block-related side effects and complications

    bleeding , hematoma , inflammation , nerve injury , hemodynamic changes

    Time frame: for 3 days

  4. Pulmonary function assessment

    Pulmonary function assessment \[forced expiratory volume at one second as % of predicted) using spirometry: Every 6 hours after extubation up to 12 hours

    Time frame: for 12 hours

  5. Intra and postoperative haemodynamic data. Heart rate

    Heart rate (beats/minute): Baseline, immediately after performing the block, at 30 minutes intervals (except when the patient on CPB) till the end of surgery Heart rate (beats/minute): Immediately after ICU admission, at 1 hour intervals in the 1st 6 hours, then at 2 hours intervals till 12 hours

    Time frame: up to 18 hours

07

Study locations

1 site
08

References and documents

Publications

  • Young I, Dunning J, Mourad F, Escaloni J, Bliton P, Fernandez-de-Las-Penas C. Clinimetric analysis of the visual analogue scale and pain free mouth opening in patients with muscular temporomandibular disorder. Cranio. 2026 Jan;44(1):143-149. doi: 10.1080/08869634.2025.2464227. Epub 2025 Feb 10. PubMed 39927871 ↗
  • Tao X, Xue FS, Hu B, Tian T. Letter to the Editor Regarding Serratus Anterior Plane Block Combined with General Analgesia and Patient-Controlled Serratus Anterior Plane Block in Patients with Breast Cancer: A Randomized Control Trial. Adv Ther. 2021 Aug;38(8):4592-4595. doi: 10.1007/s12325-021-01847-y. Epub 2021 Jul 18. No abstract available. PubMed 34275117 ↗
  • Peterson W, Tse B, Martin R, Fralick M, Sholzberg M. Evaluating hemostatic thresholds for neuraxial anesthesia in adults with hemorrhagic disorders and tendencies: A scoping review. Res Pract Thromb Haemost. 2021 May 4;5(4):e12491. doi: 10.1002/rth2.12491. eCollection 2021 May. PubMed 33977207 ↗
  • Leviel F, Fourdrain A, Delatre F, De Dominicis F, Lefebvre T, Bar S, Alshatri HY, Lorne E, Georges O, Berna P, Dupont H, Meynier J, Abou-Arab O. S erratus anterior plane block alone, paravertebral block alone and their combination in video-assisted thoracoscopic surgery: the THORACOSOPIC double-blind, randomized trial. Eur J Cardiothorac Surg. 2024 Mar 29;65(4):ezae082. doi: 10.1093/ejcts/ezae082. PubMed 38548664 ↗
  • Kwa CXW, Cui J, Lim DYZ, Sim YE, Ke Y, Abdullah HR. Discordant American Society of Anesthesiologists Physical Status Classification between anesthesiologists and surgeons and its correlation with adverse patient outcomes. Sci Rep. 2022 May 2;12(1):7110. doi: 10.1038/s41598-022-10736-5. PubMed 35501421 ↗
  • Grant MC, Chappell D, Gan TJ, Manning MW, Miller TE, Brodt JL; PeriOperative Quality Initiative (POQI) and the Enhanced Recovery After Surgery (ERAS) Cardiac Society Workgroup. Pain management and opioid stewardship in adult cardiac surgery: Joint consensus report of the PeriOperative Quality Initiative and the Enhanced Recovery After Surgery Cardiac Society. J Thorac Cardiovasc Surg. 2023 Dec;166(6):1695-1706.e2. doi: 10.1016/j.jtcvs.2023.01.020. Epub 2023 Jan 28. PubMed 36868931 ↗
  • Givtaj N, Hosseinzadeh E, Hadipourzadeh FS, Faritous Z, Askari MH, Ghanbari Garekani M. Goal-directed therapy in cardiovascular surgery: A case series study. J Cardiovasc Thorac Res. 2023;15(3):186-192. doi: 10.34172/jcvtr.2023.31838. Epub 2023 Sep 23. PubMed 38028714 ↗
  • Delijani D, Kim H, Huang X, Pena J, Hartman A, Yu PJ. Predictors of Postoperative Morphine Milligram Equivalents in Cardiac Surgery. J Cardiothorac Vasc Anesth. 2024 Dec;38(12):3094-3100. doi: 10.1053/j.jvca.2024.08.029. Epub 2024 Aug 23. PubMed 39261209 ↗
  • • Azzouzi Idrissi, O., Aouni, H., Shimi, A., Bechri, I., Derkaoui, A. & Khatouf, M.,(2024). Preoperative evaluation in cardiac surgery: A prospective study in an intensive care unit in Morocco. World Journal of Advanced Research and Reviews, 21(3), pp.2207-2213.
  • Alkhouli M, Alqahtani F, Kalra A, Gafoor S, Alhajji M, Alreshidan M, Holmes DR, Lerman A. Trends in Characteristics and Outcomes of Patients Undergoing Coronary Revascularization in the United States, 2003-2016. JAMA Netw Open. 2020 Feb 5;3(2):e1921326. doi: 10.1001/jamanetworkopen.2019.21326. PubMed 32058558 ↗
  • Albi-Feldzer A, Dureau S, Ghimouz A, Raft J, Soubirou JL, Gayraud G, Jayr C. Preoperative Paravertebral Block and Chronic Pain after Breast Cancer Surgery: A Double-blind Randomized Trial. Anesthesiology. 2021 Dec 1;135(6):1091-1103. doi: 10.1097/ALN.0000000000003989. PubMed 34618889 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Nov 2026, 10 months after the start.

Of 65 non-industry phase 1 interventional studies under Pain, Postoperative, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 30. This study's planned 10 months is below that.

Counting every sponsor, half of 83 studies reached it within 16 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2026
First posted
Nov 3, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07911943
Responsible party
Sponsor
First posted
Nov 3, 2026
Start date
Jan 1, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Nov 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion